• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    More On ARZ.TO

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Aralez Pharmaceuticals Inc. (ARZ.TO)

    -Toronto
    5.00 Down 0.17(3.29%) Apr 29, 3:53PM EDT
    ProfileGet Profile for:
    Aralez Pharmaceuticals Inc.
    151 Steeles Avenue East
    Milton, ON L9T 1Y1
    Canada - Map
    Website: http://www.aralez.com

    Details 
    Index Membership:N/A
    Sector:Basic Materials
    Industry:Gold
    Full Time Employees:12

    Business Summary 

    Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. The company engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks with or without aura in adults; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. The company also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women’s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, the company’s out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. Aralez Pharmaceuticals Inc. is headquartered in Milton, Canada. Aralez Pharmaceuticals Inc. (TSX:ARZ) operates independently of QLT Inc. as of April 05, 2016.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Aralez Pharmaceuticals Inc.

    Key Executives 
     PayExercised
    Mr. Adrian Adams , 65
    Chief Exec. Officer and Director
    1.02M0.00
    Mr. Andrew I. Koven , 58
    Pres and Chief Bus. Officer
    683.00K0.00
    Mr. Mark A. Glickman , 50
    Chief Commercial Officer
    504.00K0.00
    Mr. Scott J. Charles ,
    Chief Financial Officer
    653.00K0.00
    Mr. John E. Barnhardt CPA, 66
    Principal Accounting Officer and VP of Fin. & Admin.
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.